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Etatins and Altered
lucose Metabolism
Laboratory Curiosity
r a New Disease?
oh et al. (1), in a small number of patients given atorvastatin,
howed that despite reductions in low-density lipoprotein choles-
erol, atorvastatin treatment resulted in significant increases in
asting insulin and glycated hemoglobin levels consistent with
nsulin resistance in patients with hypercholesterolemia. These
esults are in agreement with our studies in 345,417 veteran
atients (mean age 61 years; 94% men; 6% with diabetes), which
howed that in patients without diabetes as well as those with
iabetes, fasting blood sugar increased with the use of any statin
p  0.0001) (2). After adjustment for age and the use of aspirin,
eta-blockers, and angiotensin-converting enzyme inhibitors, the
hange in fasting blood sugar in patients without diabetes using
tatins was 7 mg/dl (vs. 5 mg/dl in patients not using statins; p 
.0001), and for patients with diabetes using statins, it was 39
g/dl (vs. 32 mg/dl in patients not using statins; p  0.0001).
Sattar et al. (3) found a small but significant increase in diabetes
n patients taking statins in an analysis of the results of several
andomized controlled trials of statins.
The mechanisms by which statins may influence glucose metabo-
ism are unclear. We suggested that statins may alter glycemic control
y decreasing various metabolites, such as isoprenoid, farnesyl pyro-
hosphate, geranylgeranyl pyrophosphate, and ubiquinone, which
nhance glucose uptake via glucose transporter type 4 in adipocytes
nd impair insulin release (2).
However, further work needs to be done to define the following:
) Are the outcomes of patients who develop diabetes on statins
ifferent from those who do not? In other words, is the rise in
asting blood sugar just a laboratory curiosity or a real disease?
) Do patients who develop diabetes need to be treated similarly as
hose who develop diabetes while not taking statins? 3) How soon
fter starting statins does altered glucose metabolism become evident?
) Is the altered glucose metabolism related to the dose of statins? and
) What is the precise mechanism of altered glucose metabolism?
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e thank Dr. Mehta for commenting on our study (1). We agree
hat it is of significant clinical interest to understand potential
echanisms by which some statins have detrimental effects on
lucose homeostasis whereas other statins improve the metabolic
henotype. Sukhija et al. (2) suggested that statins alter glycemic
ontrol by decreasing various isoprenoids that enhance glucose
ptake via glucose transporter type 4 in adipocytes and contribute
o insulin release.
Recent experimental studies have demonstrated that compared
ith hydrophilic statins, lipophilic statins have pleiotropic actions
hat cause unfavorable metabolic effects, such as reduction of
nsulin secretion and exacerbation of insulin resistance (3,4). Sattar
t al. (5) showed that risk for the development of diabetes with
tatins is highest in older participants, while trials with pravastatin
ave reduced the development of diabetes in participants below a
ean age of 65 years. We previously observed that pravastatin
mproves insulin sensitivity, whereas simvastatin worsens insulin
esistance despite comparable improvements in lipid profiles and
ndothelium-dependent vasodilation in patients with hypercholes-
erolemia (6). These differential metabolic actions of lipophilic and
ydrophilic statins are consistent with recent meta-analyses (7).
mong plausible mechanisms that deserve further investigation are
otential central nervous system actions of lipophilic statins to
mpair glucose homeostasis.
Certainly, mechanisms by which atorvastatin treatment results
n increased fasting insulin and glycated hemoglobin levels require
urther investigation. Our observations are consistent with analyses
f atorvastatin therapy and the incidence of diabetes (8). It is
articularly important to investigate mechanisms of differential
etabolic effects of various statins in patients at risk for metabolic
iseases, including diabetes, obesity, and metabolic syndrome.
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rognostic Factors in
atients With Implantable
ardioverter-Defibrillators
e have read with great interest the report by Borleffs et al. (1)
bout atrial fibrillation (AF) and mortality in patients with
mplantable cardioverter-defibrillators (ICDs). The investigators
ound that AF is a prognostic factor in ICD patients, but some
ssues need to be considered.
The association between higher New York Heart Association
NYHA) functional class and poor outcome in heart failure is well
nown. Among unselected patients with NYHA functional class
I, III, and IV heart failure, mortality was 7.1%, 15.0%, and 28.0%,
espectively (2). In the study of Borleffs et al. (1), although the
roportion of patients in NYHA functional classes III and IV in
he permanent AF group was 56%, this proportion was 35% in the
aroxysmal AF group and 33% in the non-AF group. The
nvestigators state that the mortality rates in these groups were
5%, 13%, and 10%, respectively. However, it is possible that
ndependent of other prognostic factors, the discrepancy in the
roportions of patients in NYHA functional classes III and IV in
F groups may be a contributing factor to the differing mortality
ates. Therefore, specific mortality rates in NYHA groups are
eeded to correctly interpret the study’s results.
Another important issue is the types of devices used. Although
orleffs et al. (1) state the rates of single- and dual-chamber ICDs,
ome points are unclear. The investigators concluded that patients
ith permanent AF showed more than twice the risk for appro-
riate and inappropriate therapies compared with patients with no Histories of AF. However, all ICD patients, without mention of
he manufacturers and models of ICDs, were included in the study.
t is known that dual-chamber ICDs (DDD[R] ICDs and cardiac
esynchronization therapy ICDs) can easily discriminate supraven-
ricular tachycardia from ventricular tachycardia. However, single-
hamber ICDs can discriminate supraventricular tachycardia from
entricular tachycardia by using different software algorithms. For
xample, Medtronic (Minneapolis, Minnesota) ICDs use mor-
hology, stability, onset, and wavelet algorithms; Boston Scientific
Natick, Massachusetts) ICDs use atrial view, stability, and onset
lgorithms; St. Jude Medical (St. Paul, Minnesota) ICDs use
tability, onset, and atrioventricular rate branch algorithms; and
iotronik (Berlin, Germany) ICDs use stability, onset, and sus-
ained ventricular tachycardia timer algorithms (3–6). Therefore,
upraventricular tachycardia discrimination performance is also
ifferent among manufacturers and models. In addition, some
ual-chamber ICDs (e.g., Medtronic’s Virtuso, Secura, and En-
rust models and St. Jude’s Current DR and Atlas II models) can
onvert atrial tachyarrhythmias to sinus rhythm using atrial anti-
achycardia pacing and atrial cardioversion. The use of different
anufacturers and device types would result in different AF
pisodes and appropriate and inappropriate therapies. All of these
ifferences might affect the results of the study by Borleffs et al. (1).
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e thank Dr. Kalay and colleagues for their interest in and
ositive comments on our study (1). We fully agree that New York
eart Association (NYHA) functional class should be considered
